Sermorelin: Mechanism, Research Dosing, and Side Effects

What is sermorelin?

Sermorelin is a lab-made copy of the active front end of a natural hypothalamic hormone, built from the first 29 amino acids of growth-hormone-releasing hormone.

Natural GHRH is a 44-amino-acid hormone the hypothalamus makes to tell the pituitary gland to release growth hormone. Researchers found that the biological activity lives in the first 29 residues, so sermorelin is that fragment, GHRH(1-29), and it is regarded as the shortest piece of GHRH that keeps full activity (Prakash and Goa, BioDrugs 1999, PMID 18031173). Because it copies a signaling hormone rather than the hormone it triggers, sermorelin is a secretagogue: it asks the body to make more of its own growth hormone rather than adding growth hormone from outside.

This matters for how people frame it. Sermorelin is not synthetic growth hormone, not a steroid, and today not a marketed medicine in most channels. It has a real regulatory history, covered below, and a real clinical literature in children, but the current interest in adults for body composition or aging is mostly off-label or investigational and rests on thinner evidence (Walker, Clin Interv Aging 2006, PMID 18046908).

How does sermorelin work?

Sermorelin binds the GHRH receptor on the pituitary's growth-hormone-producing cells and stimulates them to release growth hormone, which then raises IGF-1.

The pituitary carries a receptor called the GHRH receptor on its somatotroph cells, the cells that store and release growth hormone. Sermorelin binds that receptor and mimics natural GHRH, prompting a burst of growth hormone into the blood (FDA Geref prescribing information; Prakash and Goa, BioDrugs 1999, PMID 18031173). Growth hormone in turn travels to the liver and other tissues and drives production of insulin-like growth factor 1 (IGF-1), the downstream signal behind many of growth hormone's effects.

Two features of this mechanism are worth understanding. First, because sermorelin acts one step upstream of the pituitary, the body's own brakes still work. The hormone somatostatin normally opposes GHRH and limits how much growth hormone is released, so a secretagogue like sermorelin tends to produce pulses rather than a flat, constant level (Walker, Clin Interv Aging 2006, PMID 18046908). Second, the effect depends on a working pituitary. If the gland cannot make growth hormone, prompting it harder will not help, which is exactly why sermorelin was useful as a diagnostic test: a normal pituitary responds, a deficient one does not (Prakash and Goa, BioDrugs 1999, PMID 18031173).

What does research report on sermorelin benefits?

The clearest published evidence is in children with idiopathic growth hormone deficiency, where sermorelin was used both to diagnose the condition and, in some children, to support growth.

For diagnosis, an intravenous dose of sermorelin was studied as a provocative test of pituitary function. Prakash and Goa (BioDrugs 1999, PMID 18031173) describe intravenous sermorelin at 1 microgram per kilogram of body weight as a rapid and relatively specific test for growth hormone deficiency, with fewer false-positive responses in children who did not have the deficiency compared with some other provocative tests. This diagnostic role is what earned the earliest FDA approval (FDA Drugs@FDA, NDA 019863).

For treatment, the same review reports that once-daily subcutaneous sermorelin at 30 micrograms per kilogram given at bedtime was effective in some prepubertal children with idiopathic growth hormone deficiency. Height velocity, meaning how fast a child grows over time, rose significantly and the increase was sustained across 12 months of treatment, and sermorelin produced catch-up growth in the majority of the growth-hormone-deficient children studied (Prakash and Goa, BioDrugs 1999, PMID 18031173). The review is candid that the effect looked modest next to injected growth hormone (somatropin), so this is a real but limited benefit in a specific pediatric group, not a general claim.

For adults, the honest picture is thinner. Interest centers on whether restoring more natural growth hormone pulses could help age-related decline in the GH axis, and Walker (Clin Interv Aging 2006, PMID 18046908) discusses that rationale for adult-onset growth hormone insufficiency. That is a hypothesis and an editorial argument, not the large controlled adult trials that would establish body-composition or anti-aging outcomes. Reporting what the pediatric trials measured is fair. Promising an adult reader a result the adult evidence has not shown is not.

What dosing does sermorelin research report?

The ranges below reflect what published studies and the historical label report. This is educational, not a prescription or a personal recommendation.

Nearly all rigorous sermorelin dosing comes from its approved pediatric use and from diagnostic testing, and those doses are set per kilogram of body weight in children. They were used under medical supervision for defined purposes and do not translate into a general adult dose. The table shows what specific sources report, with the source for each.

A note on unit math, shown generically as a reference and not as an instruction: a research dose given in micrograms only maps to an insulin-syringe "unit" reading after the peptide is dissolved in a known volume of liquid. As a generic example, if 5 mg of any peptide is dissolved in 2 mL of liquid, that is 2500 mcg per mL, and a U-100 insulin syringe reads 100 units per mL, so 1 mcg corresponds to 0.04 units on that scale. This is arithmetic for reading a label, not guidance to dose. There is no trial-validated general adult sermorelin dose, so treat any figure outside the pediatric and diagnostic literature as unestablished.

What are the side effects of sermorelin?

In its approved use, sermorelin was generally well tolerated, and the most common problem was a local reaction at the injection site.

According to the Geref prescribing information, the most common treatment-related event, occurring in about one patient in six, was a local injection reaction of pain, swelling, or redness (FDA Geref prescribing information). Other events reported in fewer than one percent of patients included headache, flushing, difficulty swallowing, nausea, and changes in taste. Prakash and Goa (BioDrugs 1999, PMID 18031173) reach the same overall conclusion: single intravenous doses and repeated once-daily subcutaneous doses were well tolerated, with transient facial flushing and pain at the injection site the most commonly reported adverse events.

Two limits are worth stating plainly. First, this safety record comes largely from children studied under supervision for diagnosis or growth hormone deficiency, so it does not automatically describe long-term use in healthy adults, where controlled safety data are limited. Second, product purity matters for any injectable research compound, which is why a certificate of analysis is worth reviewing (see /coa). None of this is a safety guarantee, and anyone raising growth hormone or IGF-1 should understand that these are powerful signals with system-wide effects.

What is the half-life of sermorelin?

Sermorelin clears from the blood very quickly, with a reported half-life of about 11 to 12 minutes.

The Geref prescribing information reports that the half-life of sermorelin is short, about 11 to 12 minutes after either intravenous or subcutaneous administration (FDA Geref prescribing information). That short window is expected for a small peptide and is one reason the historical treatment schedule used a daily bedtime dose: bedtime lines up with the body's natural nighttime growth hormone pulse, so a short-acting nudge can reinforce a rhythm the body already runs (Prakash and Goa, BioDrugs 1999, PMID 18031173). A short blood half-life does not mean the downstream effect is equally short, because the growth hormone pulse and the IGF-1 response it drives outlast the peptide itself. It does mean sermorelin is cleared fast, which shapes how it differs from longer-acting GHRH analogs discussed next.

How does sermorelin compare to CJC-1295 and tesamorelin?

All three are GHRH analogs that work through the same pituitary receptor, but they differ sharply in how long they last and in what evidence backs them.

Sermorelin is the short-acting, best-studied-in-children option, cleared in about 11 to 12 minutes (FDA Geref prescribing information). CJC-1295 is a modified GHRH analog engineered to last far longer. In healthy adults, a single subcutaneous dose of CJC-1295 raised mean growth hormone roughly 2 to 10 fold with the effect sustained about 6 days, and IGF-1 about 1.5 to 3 fold for about 9 to 11 days (Teichman et al., JCEM 2006;91(3):799-805). Tesamorelin is a stabilized GHRH analog that, unlike the other two, has a modern FDA approval: it reduced visceral fat by about 15.2 percent versus a 5.0 percent rise on placebo in adults with HIV-associated lipodystrophy and is marketed as Egrifta for that use (Falutz et al., NEJM 2007;357:2359-2370, doi:10.1056/NEJMoa072375).

Which to consider depends on the question, and none of this is a recommendation to use any of them. For a side-by-side on the growth-hormone secretagogue pairing people ask about most, see /cjc-1295-ipamorelin-dosage and /cjc-1295-ipamorelin-side-effects. It is also worth noting that CJC-1295 is often paired in research discussion with ipamorelin, a selective growth hormone secretagogue that works through a different (ghrelin) receptor with minimal effect on cortisol and prolactin (Raun et al., Eur J Endocrinol 1998;139(5):552-561), which is a distinct mechanism from all three GHRH analogs here.

Contraindications and cautions

Sermorelin is no longer a marketed medicine in most channels, so the honest position is that current human use guidance is limited, and its historical label carried specific cautions.

The clearest status fact: sermorelin was FDA-approved as Geref, first as a diagnostic agent under NDA 019863 and later for idiopathic growth hormone deficiency in children under NDA 020443 (approved September 26, 1997), and the manufacturer discontinued production in 2008 for commercial reasons (FDA Drugs@FDA). In 2013 the FDA determined that Geref had not been withdrawn for reasons of safety or effectiveness, a technical finding about why it left the market, not a clearance for general use (FDA Federal Register, March 4, 2013). Because sermorelin raises growth hormone and IGF-1, the general cautions that apply to boosting the GH axis apply here: any active or suspected cancer is a setting where raising a growth signal warrants medical caution, and pregnancy and breastfeeding are groups where investigational use of any such compound is not supported by data. Anyone considering research use should review purity documentation (/coa) and treat the absence of modern adult safety trials as a real limit, not a green light.